The inhibitory effect of connexin 32 gene on metastasis in renal cell carcinoma

Molecular Carcinogenesis

Volumn 47, Issue 6, 2008, Pages 403-409

  Sato, Hiromi ^a,b   Hagiwara, Hiromi ^a   Senba, Hironobu ^a   Fukumoto, Keiko ^a   Nagashima, Yoji ^c   Yamasaki, Hiroshi ^d   Ueno, Koichi ^b   Yano, Tomohiro ^a  

^a NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d KWANSEI GAKUIN UNIVERSITY   (Japan)

Author keywords

Connexin 32; Hypoxia; Metastasis; Renal cell carcinoma

Indexed keywords

CONNEXIN 32; PROTEIN TYROSINE KINASE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL HYPOXIA; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INOCULATION; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCID MOUSE;

ANIMALS; BASE SEQUENCE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CONNEXINS; DNA PRIMERS; HUMANS; KIDNEY NEOPLASMS; LYMPHOCYTE DEPLETION; MICE; MICE, SCID; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS;

EID: 44949185610     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20396     Document Type: Article

References (35)

1. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-417.
2. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006;49:798-805.
3. Pavlovich CP, Schmidt LS. Searching for the hereshary causes of renal-cell carcinoma. Nat Rev Cancer 2004;4:381-393.
4. Nagashima Y, Inayama Y, Kato Y, et al. Pathological and molecular biological aspects of the renal epithelial neoplasms, up-to-date. Pathol Int 2004;54:377-386
5. Law TM, Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995;76:824-832.
6. Trosko JE, Ruch RJ. Cell-cell communication in carcinogenesis. Front Biosci 1998;3:d208-d236.
7. Mesnil M. Connexins and cancer. Biol Cell 2002;94:493-500.
8. Wilgenbus KK, Kirkpatrick CJ, Knuechel R, Willecke K, Traub O. Expression of Cx26, Cx32 and Cx43 gap junction proteins in normal and neoplastic human tissues. Int J Cancer 1992;51:522-529.
9. Beyer EC, Paul DL, Goodenough DA. Connexin43: A protein from rat heart homologous to a gap junction protein from liver. J Cell Biol 1987;105:2621-2629.
10. Hirai A, Yano T, Nishikawa K, et al. Down-regulation of connexin 32 gene expression through DNA methylation in a human renal cell carcinoma cell. Am J Nephrol 2003;23: 172-177.
11. Yano T, Ito F, Satoh H, et al. Tumor-suppressive effect of connexin 32 in renal cell carcinoma from maintenance hemodialysis patients. Kidney Int 2003;63:381.
12. Fujimoto E, Satoh H, Negishi E, et al. Negative growth control of renal cell carcinoma cell by connexin 32: Possible involvement of Her-2. Mol Carcinog 2004;40:135-142.
13. Fujimoto E, Sato H, Shirai S, et al. Connexin32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line. Oncogene 2005;24:3684-3690.
14. Hagiwara H, Sato H, Shirai S, et al. Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells. Life Sci 2006;78:2249-2254.
15. Kamiya T, Kwon AH, Kanemaki T, et al. A simplified model of hypoxic injury in primary cultured rat hepatocytes. In Vitro Cell Dev Biol Anim 1998;34:131-137.
16. Yano S, Nishioka Y, Izumi K, et al. Novel metastasis model of human lung cancer in SCID mice depleted of NK cells. Int J Cancer 1996;67:211-217.
17. Martin SS, Ridgeway AG, Pinkas J, et al. A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene 2004;23:4641-4645.
18. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997;72:1-22.
19. Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci 2003;94:43-49.
20. Brahimi-Horn C, Pouyssegur J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 2006;93:E73-E80.
21. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996;32A:2451-2460.
22. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
23. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 2003;63:6130-6134.
24. Plonowski A, Serially AV, Nagy A, Kiaris H, Hebert F, Halmos G. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. Cancer Res 2000;60:2996-3001.
25. Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 2004;3:647-654.
26. Gray MJ, Zhang J, Ellis LM, et al. HIF-1alpha, STAT3, CBP/ p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005;24:3110-3120.
27. Yonezawa Y, Nagashima Y, Sato H, et al. Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells. Mol Carcinog 2005;43: 188-197.
28. Steeg PS. Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med 2006;12:895-904.
29. Kizaka-Kondoh S, lnoue M, Harada H, Hiraoka M. Tumor hypoxia: A target for selective cancer therapy. Cancer Sci 2003;94:1021-1028.
30. Duffy MJ, Duggan C. The urokinase plasminogen activator system: A rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004;37:541-548.
31. Martin SS, Leder P. Human MCF10A mammary epithelial cells undergo apoptosis following actin depolymerization that is independent of attachment and rescued by Bcl-2. Mol Cell Biol 2001;21:6529-6536.
32. Martin SS, Vuori K. Regulation of Bcl-2 proteins during anoikis and amorphosis. Biochim Biophys Acta 2004;1692: 145-157.
33. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10: 105-115.
34. Fujimoto E, Sato H, Shirai S, et al. Inhibition of Src activity enhances the tumor-suppressive effect of the connexin 32 gene in Caki-1 renal cancer cells. Oncol Rep 2006;15:1359-1365.
35. Sato H, Senba H, Virgona N, et al. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells. Mol Carcinog 2007;46:215-224.